Ownership and insider activity for enGene Holdings Inc. (ENGN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid.
Price
| Price | $1.91 |
| Market Cap | $128M |
| Exchange | NASDAQ |
| Country | CA |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-16 | Chinoporos Constantine | 75,000 | $131K | |
| 2026-07-16 | Richton Kathleen P. | |||
| 2026-07-16 | Richton Kathleen P. | 45,000 | $333K | |
| 2026-07-16 | Richton Kathleen P. | 13,900 | $132K | |
| 2026-07-16 | Richton Kathleen P. | 105,000 | $184K | |
| 2026-06-16 | Astley-Sparke Philip | A-Award | 31,000 | $54K |
| 2026-06-16 | BRUNK GERALD A | A-Award | 31,000 | $54K |
| 2026-06-16 | Glickman Richard M | A-Award | 31,000 | $54K |
| 2026-06-16 | Grossman William | A-Award | 200,000 | $350K |
| 2026-06-16 | Grossman William | A-Award | 31,000 | $54K |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.1M | $314151 | $81.5M | $173.0M | $50.2M |
| Short-term Investments | 0 | 0 | $76000 | $65.4M | $143.7M |
| Receivables | 0 | 0 | $2.3M | $1.0M | $2.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.6M | $511804 | $85.4M | $247.4M | $201.4M |
| Property, Plant & Equipment | 0 | 0 | $589000 | $2.9M | $10.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $131.4M | $132.0M | $87.0M | $311.2M | $221.5M |
| Accounts Payable | 0 | 0 | $1.2M | $1.4M | $6.7M |
| Short-term Debt | $1.0M | $1.3M | $562000 | $1.1M | $10.0M |
| Total Current Liabilities | $327447 | $893509 | $5.3M | $14.7M | $32.0M |
| Long-term Debt | 0 | 0 | $9.2M | $22.5M | $15.3M |
| Total Liabilities | $4.1M | $4.6M | $14.5M | $38.6M | $53.8M |
| Retained Earnings | -$2.3M | -$4.1M | -$199.6M | -$254.7M | -$372.0M |
| Total Equity | $127.4M | $127.4M | $72.5M | $272.6M | $167.7M |
| Total Debt | $4.2M | $32.1M | $9.8M | $25.0M | $31.8M |
| Net Debt | $3.1M | $31.8M | -$71.8M | -$213.4M | -$162.0M |
| Working Capital | $1.2M | -$381705 | $80.2M | $232.7M | $169.4M |
Financial Health
| Debt / Equity | 0.14 |
| Current Ratio | 10.21 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 0.84 |
Profitability
| Return on Equity | -2.10% |
| Return on Invested Capital | -1.61% |
| Return on Assets | -1.70% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALT · AMRN · ANNX · ANRO · CLLS · DBVT
Explore sector: Healthcare · Biotechnology
More sections of ENGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks